A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

OBJECTIVES. This study aimed to evaluate the efficacy and safety of once-per-cycle balugrastim versus pegfilgrastim for neutrophil support in breast cancer patients receiving myelosuppressive chemotherapy. METHODS. Breast cancer patients (n = 256) were randomized to 40 or 50 mg of subcutaneous balug...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Gladkov, Oleg, Moiseyenko, Vladimir, Bondarenko, Igor N., Shparyk, Yaroslav, Barash, Steve, Adar, Liat, Avisar, Noa
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2016
Aiheet:
Academia-Pharma Intersect:Breast Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4709202/
https://ncbi.nlm.nih.gov/pubmed/26668251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0152
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia